UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

Form 6-K

 


 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of November, 2015

 

Commission File Number: 001-37368

 


 

ADAPTIMMUNE THERAPEUTICS PLC

(Translation of registrant’s name into English)

 


 

101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom

(Address of principal executive offices)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x

 

Form 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes  o

 

No  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes  o

 

No  o

 

 

 



 

Other Events

 

On November 24, 2015, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC), the most common type of lung cancer, representing approximately 85 percent of lung cancers.  The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Exhibits

 

99.1 Press release dated November 24, 2015

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Adaptimmune Therapeutics plc

 

 

 

 

By:

/s/ Margaret Henry

 

Name:

Margaret Henry

 

Title:

Corporate Secretary

 

 

 

Date: November 24, 2015

 

 

 

3